Article

A Liquid Chromatography-Tandem Mass Spectrometry Method for the Quantification of Cystic Fibrosis Drugs (Caftors) in Plasma and Its Application for Therapeutic Monitoring

2025-03-05

Abstract excerpt

Cystic fibrosis (CF) is a life-threatening disorder caused by mutations in the CFTR gene, leading to defective chloride ion transport and thickened mucus in the respiratory and gastrointestinal systems. CFTR modulators, including ivacaftor, lumacaftor, tezacaftor, and elexacaftor, have improved patient outcomes, but interindividual pharmacokinetic variability and potential drug-drug interactions require therapeuti...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 6e536b80-a715-50fb-95d2-50bf0d5e4e5f
DOI: 10.20944/preprints202503.0323.v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

A Liquid Chromatography-Tandem Mass Spectrometry Method for the Quantification of Cystic Fibrosis Drugs (Caftors) in Plasma and Its Application for Therapeutic MonitoringDOI 10.20944/preprints202503.0323.v1Read

Quantitative Method for the Analysis of Ivacaftor, Hydroxymethyl Ivacaftor, Ivacaftor Carboxylate, Lumacaftor, and Tezacaftor in Plasma and Sputum Using Liquid Chromatography With Tandem Mass Spectrometry and Its Clinical Applicability.Semantic proximity Read

Isotope dilution LC-MS/MS quantification of the cystic fibrosis transmembrane conductance regulator (CFTR) modulators ivacaftor, lumacaftor, tezacaftor, elexacaftor, and their major metabolites in human serum.Semantic proximity Read

Multimatrix Monitoring of CFTR Modulators Reflecting Systemic Exposure, Airway Targeting, and Sweat Compartment in People with Cystic FibrosisSemantic proximity Read

Drug-drug interactions involving CFTR modulators: a review of the evidence and clinical implications.Semantic proximity Read

A current review of the safety of cystic fibrosis transmembrane conductance regulator modulators.Semantic proximity Read

Drug-drug interactions with CFTR modulator therapy in cystic fibrosis: Focus on Trikafta®/Kaftrio®.Semantic proximity Read

Real-time breath metabolomics to assess early response to CFTR modulators in adults with cystic fibrosis: an open-label proof-of-concept studySemantic proximity Read

Liquid chromatographic determination of lumacaftor in the presence of ivacaftor and identification of five novel degradation products using high-performance liquid chromatography ion trap time-of-flight mass spectrometry.Semantic proximity Read

A Phase 3, Open-Label Study of Lumacaftor/Ivacaftor in Children 1 to Less Than 2 Years of Age with Cystic Fibrosis Homozygous for F508del-CFTR.Semantic proximity Read

The safety of lumacaftor and ivacaftor for the treatment of cystic fibrosis.Semantic proximity Read

Therapeutic drug monitoring-guided dosing for pediatric cystic fibrosis patients: recent advances and future outlooks.Semantic proximity Read

Use of CFTR modulators in special populations, part 1: Pregnancy and lactation.Semantic proximity Read